Development of chimeric read amplification into a robust method for profiling targets of specific microRNAs and global amplification of all microRNA:mRNA pairings transcriptome-wide
Award amount
$1,999,233Program and phase
SBIR · Phase IIAward year
2021Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Eclipse Bioinnovations, Inc.
- Proposal award date
- 2021-09-22
- Contract end date
- 2023-08-31
- UEI
- NKBUXMSL35L8
- Solicitation number
- PA20-260
- Topic code
- 172
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- eMOA: A Multi-Omic Service for Mechanism of Action Determination in Drug Screening
- eMOA: A Multi-Omic Service for Mechanism of Action Determination in Drug Screening
- Unambiguous transcriptome-wide identification of microRNA:mRNA interactions through enhanced chimeric read amplification
- A robust kit, standards, and software for identifying RNA binding protein targets
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- DNA-optical barcoding technology for spatiotemporal single-cell analysis
- CRISPR-based depletion method for resolving pseudogene contamination in Next Generation Sequencing (NGS) based genetic testing
- Pioneering assays for spatially-resolved single-cell multiomics
- A Novel Instrument and Consumables for Quality Control in Next Generation Sequencing
- Sequencing of epigenetic modifications across the genome by single-molecule detection of oligonucleotide binding kinetics
Research funding history
5 SBIR/STTR records share this UEI (2017–2025). Reported award amounts total $5,376,315. Reported amounts are not federal obligations.
Phases: Phase II, Phase I, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services